HepaTx Corporation
Off-the-shelf cell therapies for liver disease
Off-the-shelf cell therapies for liver disease
HepaTx Corporation is a biotechnology startup based in the United States, founded in 2015. The company's focus is on providing off-the-shelf cell therapies for liver disease, with a vision to deliver regenerative medicine treatments that can free patients from chronic liver disease and contribute to an era where diseased and damaged tissues can be repaired. Their slogan, "Off-the-shelf cell therapies for liver disease," encapsulates their mission succinctly.
In May 2021, HepaTx Corporation received a Seed Round investment from Bioverge. This investment marks a significant milestone for the company as it seeks to advance its research and development initiatives in the field of regenerative medicine. The support from Bioverge underscores the confidence that investors have in HepaTx's innovative approach to addressing liver disease through cell therapies.
With a strong emphasis on leveraging biotechnology for addressing unmet medical needs, HepaTx Corporation is well-positioned to make a meaningful impact in the field of regenerative medicine. The recent investment signals not only financial support but also validation of the company's potential to drive advancements in the treatment of liver disease and pave the way for transformative therapies.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
20 May 2021 |
| Convertible Note | Unknown | 1 |
|
20 Dec 2020 |
| Seed Round | Unknown | 1 |
|
04 Nov 2020 |
| Seed Round | $2.10M | 6 |
|
20 Aug 2018 |
No recent news or press coverage available for HepaTx Corporation.
We care about your data, and we'd love to use cookies make your experience better.
